EMEA-001806-PIP03-18 - paediatric investigation plan

carfilzomib

Key facts

• Invented name:
  Kyprolis
• Active substance:
  carfilzomib
• Therapeutic area:
  Haematology-Hemostaseology
• Decision number:
  P/0171/2019
• PIP number:
  EMEA-001806-PIP03-18
• Pharmaceutical form(s):
  Powder for solution for infusion
• Condition(s) / indication(s):
  Treatment of Multiple Myeloma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  15/05/2019
• Compliance check done:
  No

Decision

P/0171/2019: EMA decision of 15 May 2019 on the granting of a product specific waiver for carfilzomib (Kyprolis), (EMEA-001806-PIP03-18)

Adopted Reference Number: EMA/241905/2019